SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

Melania Trump is trending as users debate the legitimacy of the associated meme coin, with community members aggressively clashing over whether the project is a sophisticated grift or a viable asset. The discourse is heavily fueled by broader political polarization and skepticism surrounding the Trump family's various ventures in the cryptocurrency space.

WorldFinancial

WorldFinancial (WLFI) is trending as the community debates potential catalysts like upcoming banking charter approval and the impact of the Clarity Act on future price action. Investors are actively discussing the token's low float and locked supply, with bullish sentiment focused on a potential supply shock while critics label the project a risk.

Everspin Technologies, Inc. engages in the provision of magnetoresistive random access memory (MRAM) solutions. Its products include Toggle MRAM, Spin-transfer Torque MRAM, TMR Sensors, and Embedded MRAM. The company was founded by Saied Tehrani on May 16, 2008 and is headquartered in Chandler, AZ.

Everspin Technologies Inc

Everspin Technologies is currently generating significant investor buzz as the community weighs its role in space exploration and mission-critical defense hardware against recent volatility and technical pullbacks. Traders are closely monitoring a potential inclusion in the Russell 2000 Index while debating whether the stock's recent price action represents a temporary accumulation phase or a deeper correction.

TOYO Co. Ltd. engages in the design, manufacture, and sale of solar cells and modules. It is involved in integrating the upstream production of wafer and silicon, midstream production of solar cell, downstream production of photovoltaic (PV) modules, and potentially other stages of the solar power supply chain. The company was founded on November 8, 2022 and is headquartered in Tokyo, Japan.

TOYO Co Ltd.

TOYO Co., Ltd

Toyo Co. is trending as investors show strong conviction in its upcoming financial updates and U.S. manufacturing expansion, despite recent volatility driven by short-selling activity and broader solar sector uncertainty. The community is focused on the company's strong fundamentals and profitability, with many traders accumulating shares ahead of anticipated analyst coverage and institutional interest.

BitGo Holdings, Inc. operates as a digital asset infrastructure company delivering custody, wallets, staking, trading, financing, stablecoins, and settlement services from regulated cold storage. It focuses on accelerating the transition of the financial system to a digital asset economy. The company was founded by Michael Belshe and Ben Davenport in 2013 and is headquartered in Sioux Falls, SD.

BitGo Holdings Inc. - Ordinary Shares - Class A

BitGo Holdings is attracting significant investor attention following the news that a firm tied to the Trump family received approval for a national trust bank charter, which may increase demand for BitGo's institutional-grade custody services. While some community members view the stock as a speculative infrastructure play tied to potential regulatory progress, others are actively debating whether current valuation levels are justified given the company's mixed earnings performance and heavy competition in the crypto space.

TRUMP is a politics-themed digital coin built on the Solana blockchain that uses the brand of Donald Trump to foster a community-driven ecosystem. As a community-focused asset, it is designed to bridge political support with web ownership, operating within the PolitiFi sector to blend political movements with decentralized finance tools. The project's main value proposition lies in its official ties to Donald Trump’s media and business brands, which allows it to provide unique physical utility such as invitations to gala dinners and meetings at Mar-a-Lago.  The token serves as the primary currency for the officially licensed Trump Billionaires Club mobile and web game, where it is used for in-game purchases and unlocking features. By leveraging the Solana blockchain, the project ensures that these in-game actions and token transfers remain fast and cost-effective. The ecosystem remains stable through a programmatic release schedule that introduces new tokens slowly to prevent supply shocks, alongside the use of specialized market makers to maintain consistent liquidity for traders.  Holders can also participate in liquidity sharing by providing their tokens to automated systems to facilitate trading for others, often earning rewards or prizes in return. Beyond digital utility, holding a specific amount of the token is a requirement for attending exclusive real-world events, including VIP parties at Mar-a-Lago. The project is managed by the Trump Meme Team and is linked with Trump Media, with an investor base that includes a wide range of retail buyers and large holders who utilize secure custody services for their assets.

Trump For President

TRUMP CRYPTO is facing intense scrutiny as community members debate allegations of it being a rug-pull scam, while supporters continue to frame it as a long-term play against perceived political sabotage. Discussions are heavily polarized, centering on the token's significant price decline and the broader controversy regarding Donald Trump's involvement in various crypto ventures.

Forte Biosciences, Inc. is a biopharmaceutical company, which engages in the provision of dermatology products and services. Its lead product includes FB-401, which is a live biotherapeutic for the treatment of inflammatory skin disease, including pediatric and adult patients with atopic dermatitis. The company was founded by Paul A. Wagner on May 3, 2017 and is headquartered in Dallas, TX.

Forte Biosciences Inc

Forte Biosciences is trending due to a definitive agreement for its acquisition by Argenx in an all-cash deal, a move that sparked significant momentum after the company's recent clinical milestones. The community is actively debating the implications of this exit for long-term shareholders while monitoring the stock's price action as it stabilizes near the acquisition offer level.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing strong community interest driven by the growth of Briumvi and high anticipation for its subcutaneous formulation, which has fueled persistent buyout speculation. Investors are closely watching for updates on commercial execution and potential strategic interest from larger biopharma players in light of positive market share momentum.

Sui s a Layer 1 blockchain developed by Mysten Labs, a team founded by former lead engineers from Meta’s blockchain research division. It is designed for global adoption by providing a secure, high-speed environment for digital asset ownership and removing technical barriers for Web3 applications. The platform utilizes the Move programming language to create a safe framework and supports horizontal scaling to keep fees stable and speeds high as the network grows. Significant institutional support comes from major venture capital firms including Andreessen Horowitz, Coinbase Ventures, Circle Ventures, and YZi Labs.  The system functions by organizing data into independent objects rather than a single ledger of accounts. This object-centric data model enables parallel execution, allowing the network to process many transactions simultaneously instead of waiting for one to finish before starting the next. This architecture is built for rapid transaction finalization to ensure near-instant results. To maintain long-term stability, the network collects fees into a storage fund that rewards validators for keeping data on the network indefinitely.  Sui offers several advanced tools including zkLogin for easier account access and sponsored transactions that allow users to interact with apps without managing complex wallets or immediate fees. Developers can also create tailored object types that work across the entire network, which encourages innovation and deep composability. These features are designed to create a more user-friendly experience for interacting with decentralized applications and digital games.  The SUI token is central to the ecosystem, serving as the primary asset for transaction fees and on-chain utility within decentralized exchanges and lending platforms. Users participate in a proof-of-stake mechanism by locking their tokens to support validators and secure the blockchain in exchange for rewards. Additionally, token holders have a role in governance, allowing them to participate in voting on network rules and future protocol upgrades. Value moves through the system through these staking rewards and transaction fees to ensure the platform scales sustainably

SUI is experiencing significant market interest driven by community expectations of a bullish cycle, with investors actively discussing potential supply shocks from token staking and institutional participation. While some participants express frustration over past technical issues, many in the community remain focused on the network's long-term utility and potential for price appreciation as the broader altcoin sector shifts toward increased momentum.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors react to encouraging phase 2 results for Ivonescimab in triple-negative breast cancer, fueling community optimism about the drug's expanding potential across multiple indications. Despite ongoing debates regarding data quality and trial design compared to established industry standards, shareholders are closely watching for further clinical validation as they look toward future regulatory milestones.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

PAVmed (PAVM) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results

PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results PAVmed Provides Business Update and Reports Second Quarter 2026 Financial Results PR Newswire NEW YORK, Aug. 14, 2026 Veris Health accelerated its commercial engagement with OSU-The JamesVeris Health implantable...

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results

Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results Lucid Diagnostics Provides Business Update and Reports Second Quarter 2026 Financial Results PR Newswire NEW YORK, Aug. 13, 2026 Recognized 2Q26 revenue of $1.5 millionProcessed 2,770 EsoGuard testsSecured...

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard Esophageal DNA Test

Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard Esophageal DNA Test Lucid Diagnostics Secures Commercial Coverage Policy Spanning Multiple Health Plans for its EsoGuard Esophageal DNA Test PR Newswire NEW YORK, Aug. 5, 2026 Concert's policy...

Lucid Diagnostics to Participate in Upcoming Investor Conferences

Lucid Diagnostics to Participate in Upcoming Investor Conferences Lucid Diagnostics to Participate in Upcoming Investor Conferences PR Newswire NEW YORK, Aug. 4, 2026 NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc.(Nasdaq: LUCD)("Lucid" or the "Company"), a commercial-stage, cancer...

PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026

PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026 PAVmed to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 14, 2026 PR Newswire NEW YORK, July 31, 2026 Conference Call and Webcast at 8:30 AM ETNEW YORK, July 31, 2026...

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026

Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 Lucid Diagnostics to Hold Second Quarter 2026 Business Update Conference Call and Webcast on August 13, 2026 PR Newswire NEW YORK, July 30, 2026 Conference Call and Webcast at 8:30 AM ETNEW...

PAVmed (PAVM) Q4 2025 Earnings Transcript

@media (max-width: 768px) { .image-container { width: 100% !important; float: none !important; margin: 0 0 1rem 0 !important; } } Image source: The Mo...

PAVmed (PAVM) Q1 2026 Earnings Transcript

PAVmed Inc. (PAVM) Reports Q1 Loss, Lags Revenue Estimates

PAVmed (PAVM) delivered earnings and revenue surprises of -69.57% and -78.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

$PAVM Q2 &#39;26 Earnings Results &amp; Recap

• Reported GAAP EPS of -$0.87 up 96.06% YoY
• Reported revenue of $0.03M up 450.00% YoY

Stocktwits

PAVmed Inc

 Q2 '26 Earnings Results & Recap

• Reported GAAP EPS of -$0.87 up 96.06% YoY
• Reported revenue of $0.03M up 450.00% YoY

This account has been verified as an official STOCKTWITS representative.

Verified Account

Stocktwits Earnings

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVM Stock Shot Up Over 250% Today – What’s The Deal With The Department of Veterans Affairs?

Equity

Bullish Sentiment

Up more than 1% 

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a winning week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

PAVMPAVmed Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest PAVM News